Literature DB >> 31597754

The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation.

Melissa-Rose Abrahams1, Sarah B Joseph2,3, Nigel Garrett4, Lynn Tyers1, Matthew Moeser3, Nancie Archin5, Olivia D Council2, David Matten1, Shuntai Zhou3, Deelan Doolabh1, Colin Anthony1, Nilu Goonetilleke2,5, Salim Abdool Karim4,6, David M Margolis2,5, Sergei Kosakovsky Pond7, Carolyn Williamson8,9, Ronald Swanstrom10,11.   

Abstract

Although antiretroviral therapy (ART) is highly effective at suppressing HIV-1 replication, the virus persists as a latent reservoir in resting CD4+ T cells during therapy. This reservoir forms even when ART is initiated early after infection, but the dynamics of its formation are largely unknown. The viral reservoirs of individuals who initiate ART during chronic infection are generally larger and genetically more diverse than those of individuals who initiate therapy during acute infection, consistent with the hypothesis that the reservoir is formed continuously throughout untreated infection. To determine when viruses enter the latent reservoir, we compared sequences of replication-competent viruses from resting peripheral CD4+ T cells from nine HIV-positive women on therapy to viral sequences circulating in blood collected longitudinally before therapy. We found that, on average, 71% of the unique viruses induced from the post-therapy latent reservoir were most genetically similar to viruses replicating just before ART initiation. This proportion is far greater than would be expected if the reservoir formed continuously and was always long lived. We conclude that ART alters the host environment in a way that allows the formation or stabilization of most of the long-lived latent HIV-1 reservoir, which points to new strategies targeted at limiting the formation of the reservoir around the time of therapy initiation.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2019        PMID: 31597754     DOI: 10.1126/scitranslmed.aaw5589

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  64 in total

Review 1.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.

Authors:  Blake J Rust; Leslie S Kean; Lucrezia Colonna; Katherine E Brandenstein; Nikhita H Poole; Willimark Obenza; Mark R Enstrom; Colby R Maldini; Gavin I Ellis; Christine M Fennessey; Meei-Li Huang; Brandon F Keele; Keith R Jerome; James L Riley; Hans-Peter Kiem; Christopher W Peterson
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

3.  GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture.

Authors:  Anne Bruggemans; Gerlinde Vansant; Mini Balakrishnan; Michael L Mitchell; Ruby Cai; Frauke Christ; Zeger Debyser
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

4.  Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4+ T Cell Subsets during Long-Term Combination Antiretroviral Therapy.

Authors:  Bradley R Jones; Rachel L Miller; Jeffrey B Joy; Zabrina L Brumme; Natalie N Kinloch; Olivia Tsai; Hawley Rigsby; Hanwei Sudderuddin; Aniqa Shahid; Bruce Ganase; Chanson J Brumme; Marianne Harris; Art F Y Poon; Mark A Brockman; Rémi Fromentin; Nicolas Chomont
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

Review 5.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

6.  Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Authors:  Marina Tuyishime; Carolina Garrido; Shalini Jha; Matt Moeser; Dieter Mielke; Celia LaBranche; David Montefiori; Barton F Haynes; Sarah Joseph; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

7.  The gift of a lifetime: analysis of HIV at autopsy.

Authors:  Frank Maldarelli
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

8.  Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.

Authors:  Mangaiarkarasi Asokan; Joana Dias; Cuiping Liu; Anna Maximova; Keenan Ernste; Amarendra Pegu; Krisha McKee; Wei Shi; Xuejun Chen; Cassandra Almasri; Wanwisa Promsote; David R Ambrozak; Lucio Gama; Jianfei Hu; Daniel C Douek; John-Paul Todd; Jeffrey D Lifson; Slim Fourati; Rafick P Sekaly; Andrew R Crowley; Margaret E Ackerman; Sung Hee Ko; Divya Kilam; Eli A Boritz; Laura E Liao; Katharine Best; Alan S Perelson; John R Mascola; Richard A Koup
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-20       Impact factor: 11.205

Review 9.  Curing HIV: Seeking to Target and Clear Persistent Infection.

Authors:  David M Margolis; Nancie M Archin; Myron S Cohen; Joseph J Eron; Guido Ferrari; J Victor Garcia; Cynthia L Gay; Nilu Goonetilleke; Sarah B Joseph; Ronald Swanstrom; Anne-Marie W Turner; Angela Wahl
Journal:  Cell       Date:  2020-03-26       Impact factor: 41.582

10.  Primer ID Next-Generation Sequencing for the Analysis of a Broad Spectrum Antiviral Induced Transition Mutations and Errors Rates in a Coronavirus Genome.

Authors:  Shuntai Zhou; Collin S Hill; Michael U Clark; Timothy P Sheahan; Ralph Baric; Ronald Swanstrom
Journal:  Bio Protoc       Date:  2021-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.